

Ariane C Gomes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4298672/publications.pdf>

Version: 2024-02-01

14
papers

529
citations

840119

11
h-index

1058022

14
g-index

14
all docs

14
docs citations

14
times ranked

938
citing authors

#	ARTICLE	IF	CITATIONS
1	IgA binds to the AD α 2 epitope of glycoprotein B and neutralizes human cytomegalovirus. <i>Immunology</i> , 2021, 162, 314-327.	2.0	5
2	NK Cell Memory to Cytomegalovirus: Implications for Vaccine Development. <i>Vaccines</i> , 2020, 8, 394.	2.1	8
3	Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands—A Role for CCL2. <i>Frontiers in Immunology</i> , 2019, 10, 1679.	2.2	10
4	The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation. <i>Vaccines</i> , 2019, 7, 67.	2.1	12
5	Type of RNA Packed in VLPs Impacts IgG Class Switching—Implications for an Influenza Vaccine Design. <i>Vaccines</i> , 2019, 7, 47.	2.1	38
6	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 1015.	2.2	39
7	Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation. <i>EBioMedicine</i> , 2019, 50, 45-54.	2.7	12
8	Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. <i>Vaccines</i> , 2018, 6, 37.	2.1	113
9	Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. <i>Journal of Controlled Release</i> , 2017, 251, 92-100.	4.8	69
10	Harnessing Nanoparticles for Immunomodulation and Vaccines. <i>Vaccines</i> , 2017, 5, 6.	2.1	113
11	Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against <i>Plasmodium berghei/vivax</i> . <i>Vaccines</i> , 2017, 5, 10.	2.1	28
12	Microcrystalline Tyrosine (MCT $\hat{\text{A}}$): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. <i>Vaccines</i> , 2017, 5, 32.	2.1	15
13	Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines. <i>Frontiers in Immunology</i> , 2017, 8, 226.	2.2	40
14	Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. <i>PLoS ONE</i> , 2017, 12, e0181844.	1.1	27